These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14281108)

  • 21. ENZYME-ALTERABLE ALKYLATING AGENTS. VII. THE DESIGN OF SHORT-LIVED MUSTARDS.
    SASS S; WILLIAMSON CE; KRAMER SP; GOODMAN LE; ULFOHN A; SELIGMAN AM; WITTEN B
    J Med Chem; 1965 Jan; 8():14-7. PubMed ID: 14287258
    [No Abstract]   [Full Text] [Related]  

  • 22. Experimental chemotherapy studies. II. The reactions of chloroquine mustard (CQM) and nitrogen mustard (HN2) with Ehrlich cells.
    RUTMAN RJ; STEELE WJ; PRICE CC
    Cancer Res; 1961 Oct; 21():1134-40. PubMed ID: 14495507
    [No Abstract]   [Full Text] [Related]  

  • 23. EXPERIMENTAL CHEMOTHERAPY STUDIES. IV. THE PROTECTIVE ACTION OF MERCAPTOALKYLAMINES AGAINST ALKYLATING AGENTS.
    RUTMAN RJ; LEWIS FS; PRICE CC
    Cancer Res; 1964 May; 24():626-33. PubMed ID: 14188465
    [No Abstract]   [Full Text] [Related]  

  • 24. [INDUCTION OF METASTASES BY TREATMENT WITH CARCINOSTATIC AGENTS. II. DEPRESSION OF HOST RESISTANCE AND ANTIBODY PRODUCTION].
    KONDO T; ICHIHASHI H
    Gan; 1964 Oct; 55():403-10. PubMed ID: 14247590
    [No Abstract]   [Full Text] [Related]  

  • 25. THE TREATMENT OF CANCER BY ISOLATION PERFUSION.
    DONALDSON SS; FLETCHER WS
    Am J Nurs; 1964 Aug; 64():81-4. PubMed ID: 14180364
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparative investigation of the chemotherapeutic action of N-oxide-mustard gas and other alkylating compounds in rat tumors].
    DANNEBERG P; DRUCKREY H; KAISER K; LO HW; MECKE R; NIEPER HA; SCHMAHL D
    Arzneimittelforschung; 1956 Sep; 6(9):539-50. PubMed ID: 13373668
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
    Singh RK; Kumar S; Prasad DN; Bhardwaj TR
    Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. POTENTIAL ANTICANCER AGENTS. IV. HETEROCYCLIC PHOSPHORAMIDE NITROGEN MUSTARDS.
    ZIMMER H; SILL AD
    Arzneimittelforschung; 1964 Feb; 14():150-1. PubMed ID: 14229652
    [No Abstract]   [Full Text] [Related]  

  • 29. THE ADVERSE EFFECTS OF CANCER CHEMOTHERAPY.
    KONDO T
    Acta Unio Int Contra Cancrum; 1964; 20():194-8. PubMed ID: 14151882
    [No Abstract]   [Full Text] [Related]  

  • 30. EXPERIMENTAL CHEMOTHERAPY STUDIES. 3. PROPERTIES OF DNA FROM ASCITES CELLS TREATED IN VIVO WITH NITROGEN MUSTARD.
    GOLDER RH; MARTIN-GUZMAN G; JONES J; GOLDSTEIN NO; ROTENBERG S; RUTMAN RJ
    Cancer Res; 1964 Jul; 24():964-8. PubMed ID: 14198245
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
    Goldenberg GJ
    Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOME MORPHOLOGICAL EFFECTS OF ALKYLATING AGENTS.
    BIESELE JJ
    Exp Cell Res; 1963; 24():SUPPL9:525-34. PubMed ID: 14046252
    [No Abstract]   [Full Text] [Related]  

  • 33. [NITROGEN MUSTARDS AS ALKYLATING AGENTS].
    MANACORDA G; POMINI A
    Minerva Farm; 1964; 13():89-94. PubMed ID: 14268580
    [No Abstract]   [Full Text] [Related]  

  • 34. UTILIZATION OF DNA AND RNA PRECURSORS AS INDICATORS OF DRUG EFFECT ON CANCER CELLS. ANL-6723.
    STROUD AN; MCDONALD GO; SVOBODA BR; BRUES AM
    ANL Rep; 1963 May; ():237-42. PubMed ID: 14131021
    [No Abstract]   [Full Text] [Related]  

  • 35. [Evaluation of the specificity of anti-proliferative drugs. Comparison of nitrogen mustard, triethylene melamine and cyclophosphamide].
    SCALTRINI GC; TOGNELLA S; CONIGLIARO S; GRIFONI V
    Haematol Lat; 1961; 4():411-22. PubMed ID: 14497771
    [No Abstract]   [Full Text] [Related]  

  • 36. LONG TERM RESULTS ACHIEVED WITH THE USE OF ALKYLATING AGENTS IN MALIGNANT LYMPHOMA AND HODGKIN'S DISEASE.
    PAPAC RJ; WOOD DA
    Acta Unio Int Contra Cancrum; 1964; 20():377-9. PubMed ID: 14151934
    [No Abstract]   [Full Text] [Related]  

  • 37. THE TREATMENT OF CARCINOMA IN DOGS' BLADDERS WITH CYTOTOXIC DRUGS.
    BOYLAND E; KINDER CH; WILLIAMS K
    Invest Urol; 1965 Mar; 2():446-52. PubMed ID: 14261785
    [No Abstract]   [Full Text] [Related]  

  • 38. NECROTIZING TOXOPLASMIC ENCEPHALITIS AND HERPETIC PNEUMONIA COMPLICATING TREATED HODGKIN'S DISEASE. REPORT OF A CASE.
    CHEEVER AW; VALSAMIS MP; RABSON AS
    N Engl J Med; 1965 Jan; 272():26-9. PubMed ID: 14219210
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of DNA repair inhibitors on e response of tumors treated with x-ray and alkylating agents.
    Gaudin D; Yielding KL; Stabler A; Brown J
    Proc Soc Exp Biol Med; 1971 May; 137(1):202-6. PubMed ID: 5581662
    [No Abstract]   [Full Text] [Related]  

  • 40. COMPARISON OF THE EFFECTS OF SOME RADIATION MODIFIERS ON SELECTED RADIOMIMETIC AGENTS IN MICROORGANISMS.
    PITTILLO RF; NARKATES AJ; BURNS J
    Radiat Res; 1965 Jun; 25():401-9. PubMed ID: 14295129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.